Acta Mol
According to the Cleveland Clinic, GLP-1 receptor agonists are reshaping obesity treatment and helping patients achieve meaningful, sustained weight loss
Semaglutide A GLP-1 receptor agonist originally developed for diabetes treatment Helps regulate appetite and metabolic processes Typical weight loss: Up to 15% of body weight Administered as a weekly subcutaneous injection Tirzepatide Dual GIP and GLP-1 receptor agonist More recent medication with potentially more significant weight loss Typical weight loss: Up to 20-22% of body weight Weekly subcutaneous injection The Science Behind Our Treatments Semaglutide and Tirzepatide aren't just medicationsthey're breakthrough tools that communicate directly with your body's hunger and metabolism systems
Zhao P, Wong KI, Sun X, Reilly SM, Uhm M, Liao Z, et al
Nutraceutical-grade oils typically contain 1000 mg/kg or higher, with some ultra-high polyphenol varieties exceeding 2,000 mg/kg
Weight loss was also observed, and since weight management is often recommended for adults with type 2 diabetes, this finding was a beneficial side effect of taking the medication
